title: The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
abstract: Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.
authors.affiliation: Department of Psychiatry, UMDNJ, Robert Wood Johnson Medical School, D317, 675 Hoes Lane, Piscataway, NJ 08854, USA. dobkinro@umdnj.edu
authors.forename: Roseanne DeFronzo
authors.initials: RD
authors.lastname: Dobkin
authors.forename: Matthew
authors.initials: M
authors.lastname: Menza
authors.forename: Karina L
authors.initials: KL
authors.lastname: Bienfait
authors.forename: Michael
authors.initials: M
authors.lastname: Gara
authors.forename: Humberto
authors.initials: H
authors.lastname: Marin
authors.forename: Margery H
authors.initials: MH
authors.lastname: Mark
authors.forename: Allison
authors.initials: A
authors.lastname: Dicke
authors.forename: Alexander
authors.initials: A
authors.lastname: Tröster
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009661:Nortriptyline / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D017374:Paroxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D017374:Paroxetine; D009661:Nortriptyline
references.citation: J Neuropsychiatry Clin Neurosci. 2006 Summer;18(3):377-83
references.pmid: 16963587
references.citation: J Psychiatr Res. 1975 Nov;12(3):189-98
references.pmid: 1202204
references.citation: J Neurol Sci. 2006 Oct 25;248(1-2):131-7
references.pmid: 16780884
references.citation: Biol Psychiatry. 2005 Aug 1;58(3):204-10
references.pmid: 16018984
references.citation: Dement Geriatr Cogn Disord. 2005;20(2-3):140-4
references.pmid: 16020942
references.citation: Am J Psychiatry. 2000 Dec;157(12):1949-54
references.pmid: 11097959
references.citation: J Neurol Neurosurg Psychiatry. 1992 May;55(5):377-82
references.pmid: 1602311
references.citation: Am J Psychiatry. 1992 Apr;149(4):443-54
references.pmid: 1372794
references.citation: J Neurol Sci. 2006 Oct 25;248(1-2):151-7
references.pmid: 16797028
references.citation: Am J Geriatr Psychiatry. 2008 Sep;16(9):752-9
references.pmid: 18697883
references.citation: Psychol Med. 2004 Jan;34(1):125-36
references.pmid: 14971633
references.citation: Arch Neurol. 1995 Dec;52(12):1164-9
references.pmid: 7492290
references.citation: J Psychosom Res. 1998 Jul;45(1):5-13
references.pmid: 9720850
references.citation: Br J Med Psychol. 1959;32(1):50-5
references.pmid: 13638508
references.citation: Neurology. 2007 Jul 24;69(4):342-7
references.pmid: 17581943
references.citation: J Psychiatr Res. 2003 Mar-Apr;37(2):99-108
references.pmid: 12842163
references.citation: Eur J Neurol. 2005 Jan;12(1):9-15
references.pmid: 15613141
references.citation: Neurology. 2009 Mar 10;72(10):886-92
references.pmid: 19092112
references.citation: Mov Disord. 2009 Jul 15;24(9):1325-32
references.pmid: 19412944
references.citation: BMJ. 1993 May 29;306(6890):1437-40
references.pmid: 8518639
references.citation: J Am Geriatr Soc. 1997 Jul;45(7):844-9
references.pmid: 9215336
references.citation: Arch Neurol. 1996 Feb;53(2):175-9
references.pmid: 8639068
references.citation: Arch Clin Neuropsychol. 2007 Aug;22(6):711-8
references.pmid: 17644304
references.citation: Neurology. 1995 Apr;45(4):672-6
references.pmid: 7723954
references.citation: Arch Neurol. 1997 Aug;54(8):982-6
references.pmid: 9267973
references.citation: J Neuropsychiatry Clin Neurosci. 2002 Winter;14(1):31-6
references.pmid: 11884652
references.citation: Arch Neurol. 1992 Mar;49(3):305-7
references.pmid: 1536634
references.citation: Eur J Neurol. 1998 May;5(3):291-295
references.pmid: 10210845
references.citation: Neuropsychologia. 2007 Jun 18;45(11):2499-507
references.pmid: 17507058
references.citation: Adv Neurol. 1990;53:245-9
references.pmid: 2239463
references.citation: Int J Geriatr Psychiatry. 2003 Jul;18(7):571-6
references.pmid: 12833300